Cells for Cells

Santiago, Chile

Cells for Cells

Santiago, Chile
SEARCH FILTERS
Time filter
Source Type

News Article | December 1, 2016
Site: www.prnewswire.co.uk

SAN JUAN, Puerto Rico, 1. Dezember 2016 /PRNewswire/ -- In den letzten zwei Tagen war Puerto Rico im Rahmen der Biolatam® 2016 das Zentrum der Biowissenschaften, in dem mehr als 250 führende Kräfte der Branchen Biotechnik, Pharmazie und Technologie zusammenkamen, um Kontakte zu knüpfen und über Innovationen zu sprechen. Die Veranstaltung der EBD Group in Zusammenarbeit mit ASEBIO ermöglichte Puerto Rico, seine dynamische Biowissenschafts-Community zu präsentieren. Zudem eröffnete sie Führungskräften des Bereichs Biopharma aus der ganzen Welt Möglichkeiten für Partnerschaften und Investitionen. Die diesjährige Biolatam wurde von 142 Firmen aus 24 Ländern besucht. Die Teilnehmer kamen aus Unternehmen der Pharmazie und Biotechnik, Behörden, Universitäten, Branchenverbänden und Firmen der Bereiche Risikokapital, Private Equity and institutionelle Anleger. Diese breit gefächerte Gruppe bildete die ideale Umgebung für programmatische Gespräche u. a. über Produktion in Lateinamerika, klinische Studien und den Zyklus der Medikamentenentwicklung, sowie Prävention und Diagnose von Tropenkrankheiten. In der Veranstaltung fand sich ein vollständiges Programm von Podiumsveranstaltungen mit bekannten Rednern, Präsentationen innovativer lateinamerikanischer Firmen und einer interessanten Ausstellung. Teilnehmer konnten mit der partneringONE®-Software 30-minütige Meetings ansetzen. Dies gewährte Teilnehmern die Möglichkeit zum Kennenlernen und Knüpfen von Verbindungen für die Zusammenarbeit in unterschiedlichen Feldern. „Biolatam gibt uns die Möglichkeit, der lateinamerikanischen Community die Türen zu öffnen. Für Puerto Rico ist Wissenschaft entscheidend für Entwicklung und wirtschaftliches Wachstum. Die Insel verfügt über große Biodiversität und die geografische Lage macht sie zusammen mit den verfügbaren Anreizen zu einem sehr guten Standort für die Expansion von Unternehmen. Wenn Firmen Puerto Rico als Möglichkeit für ihre Expansion in Betracht ziehen, treibt dies das Wachstum und bildet für unseren Wissenschaftsbereich weiterhin einen viel versprechenden Weg", sagte Lucy Crespo, CEO des Puerto Rico Science, Technology and Research Trust. „Die diesjährige Veranstaltung brachte führende Kräfte des Bereiches Biopharmazie aus der ganzen Welt nach Puerto Rico, die nach Möglichkeiten Ausschau halten, ihre geschäftliche Tätigkeit in Lateinamerika zu expandieren. Die Möglichkeit, mit so vielen führenden Kräften der Branche Kontakte zu knüpfen, ist definitiv der Schlüssel künftiger geschäftlicher Entwicklung. Unsere Teilnehmer haben wertvolle Kontakte geknüpft, welche zu den Erfolgsgeschichten, welche die Biolatam jedes Jahr schreibt, hinzutreten werden", sagte Anna Chrisman, Group Managing Director der EBD Group. Zu den herausragenden Rednern der Veranstaltung gehörten: Rolando Castro, CEO von Cognitiva IBM Watson Strategic Partner; Eugenio Torres, Managing Partner bei Ferraiuoli LLC; Sebastián Vidal, Executive Director von Parallel18; Carola Schropp, Managing Director der Hayim Group; Maroun Khoury, Chief Scientific Officer bei Cells for Cells und Morrie Ruffin, Managing Partner bei Adjuvant Partners and Managing Director der Alliance for Regenerative Medicine. Weitere Informationen: Folgen Sie Biolatam auf Twitter: @EBDGroup (hashtag #Biolatam) oder auf Facebook. Über die EBD Group Die EBD Group ist die führende Firma für den Aufbau von Partnerschaften in der globalen Biowissenschaftsbranche. Unternehmen aus Biotechnologie, Pharmazie und Medizintechnik nutzen seit 1993 die Partnering-Konferenzen der EBD Group und ihre Technik und Dienstleistungen, um die für den Erfolg entscheidenden Geschäftsmöglichkeiten zu finden und strategische Partnerschaften aufzubauen. Zu den Konferenzen der EBD Group, die mit Unterstützung durch namhafte Unternehmen und internationale Branchenverbände veranstaltet werden, gehören: Der ausgereifte, webbasierte Partnering-Service der EBD Group unter der Bezeichnung partneringONE® wird auf zahlreichen Veranstaltungen von Drittanbietern in aller Welt zum Auffinden geeigneter Partner genutzt und partnering360® ist die offene Internet-Community von Entscheidungsträgern in den Biowissenschaften, die ganzjährig der Stärkung von Partnerschaften dient. Nutzen Sie auch Insight der EBD Group, um neueste und strategisch wichtige Nachrichten der Branche der Biowissenschaften zu verfolgen. Die EBD Group ist ein Unternehmen der Informa. Informa ist der weltweit größte börsennotierte Organisator von Messen, Konferenzen und Schulungen Die EBD Group unterhält Büros in den USA und in Europa. Weitere Informationen erhalten Sie unter www.ebdgroup.com.


Alcayaga-Miranda F.,University of Los Andes, Chile | Gonzalez P.L.,University of Los Andes, Chile | Lopez-Verrilli A.,Cells for Cells | Varas-Godoy M.,University of Los Andes, Chile | And 3 more authors.
Oncotarget | Year: 2016

Mesenchymal stem cells (MSCs) secrete exosomes that are capable of modifying the tumor environment through different mechanisms including changes in the cancercell secretome. This activity depends on their cargo content that is largely defined by their cellular origin. Endometrial cells are fine regulators of the angiogenic process during the menstrual cycle that includes an angiostatic condition that is associated with the end of the cycle. Hence, we studied the angiogenic activity of menstrual stem cells (MenSCs)-secreted exosomes on prostate PC3 tumor cells. Our results showed that exosomes induce a reduction in VEGF secretion and NF-λB activity. Lower reactive oxygen species (ROS) production in exosomes-treated cells was detected by the DCF method, suggesting that the inhibition of the intracellular ROS impacts both NF-λB and VEGF pathways. We confirmed using tubule formation and plug transplantation assays that MenSCs-exosomes suppress the secretion of pro-angiogenic factors by the PC3 cells in a ROS-dependent manner. The inhibition of the tumor angiogenesis and, consequently, the tumor growth was also confirmed using a xenograft mouse model. Additionally, the anti-tumoral effect was associated with a reduction of tumor hemoglobin content, vascular density and inhibition of VEGF and HIF-1β expression. Importantly, we demonstrate that the exosomes anti-angiogenic effect is specific to the menstrual cell source, as bone marrow MSCs-derived exosomes showed an opposite effect on the VEGF and bFGF expression in tumor cells. Altogether, our results indicate that MenSCs-derived exosomes acts as blockers of the tumor-induced angiogenesis and therefore could be suitable for anti-cancer therapies.


PubMed | Cells for Cells, Consorcio Regenero and University of Los Andes, Chile
Type: Journal Article | Journal: Oncotarget | Year: 2016

Mesenchymal stem cells (MSCs) secrete exosomes that are capable of modifying the tumor environment through different mechanisms including changes in the cancer-cell secretome. This activity depends on their cargo content that is largely defined by their cellular origin. Endometrial cells are fine regulators of the angiogenic process during the menstrual cycle that includes an angiostatic condition that is associated with the end of the cycle. Hence, we studied the angiogenic activity of menstrual stem cells (MenSCs)-secreted exosomes on prostate PC3 tumor cells. Our results showed that exosomes induce a reduction in VEGF secretion and NF-B activity. Lower reactive oxygen species (ROS) production in exosomes-treated cells was detected by the DCF method, suggesting that the inhibition of the intracellular ROS impacts both NF-B and VEGF pathways. We confirmed using tubule formation and plug transplantation assays that MenSCs-exosomes suppress the secretion of pro-angiogenic factors by the PC3 cells in a ROS-dependent manner. The inhibition of the tumor angiogenesis and, consequently, the tumor growth was also confirmed using a xenograft mouse model. Additionally, the anti-tumoral effect was associated with a reduction of tumor hemoglobin content, vascular density and inhibition of VEGF and HIF-1 expression. Importantly, we demonstrate that the exosomes anti-angiogenic effect is specific to the menstrual cell source, as bone marrow MSCs-derived exosomes showed an opposite effect on the VEGF and bFGF expression in tumor cells. Altogether, our results indicate that MenSCs-derived exosomes acts as blockers of the tumor-induced angiogenesis and therefore could be suitable for anti-cancer therapies.


Alcayaga-Miranda F.,University of Los Andes, Chile | Cuenca J.,University of Los Andes, Chile | Luz-Crawford P.,Cells for Cells | Luz-Crawford P.,French Institute of Health and Medical Research | And 4 more authors.
Stem Cell Research and Therapy | Year: 2015

Introduction: Stem cells isolated from menstrual fluid (MenSCs) exhibit mesenchymal stem cell (MSCs)-like properties including multi-lineage differentiation capacity. Besides, menstrual fluid has important advantages over other sources for the isolation of MSCs, including ease of access and repeated sampling in a noninvasive manner. Such attributes allow the rapid culture of MenSCs in numbers that are sufficient for therapeutical doses, at lower cell passages. Methods: In this study, we advance the characterization of MenSC populations in comparison to bone marrow derived mesenchymal stem cells (BM-MSCs) with regards to proliferation, lineage differentiation, migration potential, secretion profile and angiogenic properties in vitro and in a matrigel plug assay in mice. We additionally tested their ability to support hematopoietic stem cell (HSC) expansion in vitro. Results: The phenotypic analysis of MenSCs revealed a profile largely similar to the BM-MSCs with the exception of a higher expression of the adhesion molecule CD49a (alpha1-integrin). Furthermore, the fibroblast colony forming units (CFU-F) from MenSCs yielded a 2 to 4 fold higher frequency of progenitors and their in vitro migration capacity was superior to BM-MSCs. In addition, MenSCs evidenced a superior paracrine response to hypoxic conditions as evidenced by the secretion of vascular endothelial growth factor and basic fibroblast growth factor and also improved angiogenic effect of conditioned media on endothelial cells. Furthermore, MenSCs were able to induce angiogenesis in a matrigel plug assay in vivo. Thus, an 8-fold increase in hemoglobin content was observed in implanted plugs containing MenSCs compared to BM-MSCs. Finally, we demonstrated, for the first time, the capacity of MenSCs to support the ex-vivo expansion of HSCs, since higher expansion rates of the CD34∈+∈CD133+ population as well as higher numbers of early progenitor (CFU-GEMM) colonies were observed in comparison to the BM source. Conclusions: We present evidence showing superiority of MenSCs with respect to several functional aspects, in comparison with BM-MSCs. However, the impact of such properties in their use as adult-derived stem cells for regenerative3 medicine remains to be clarified. © 2015 Alcayaga-Miranda et al.; licensee BioMed Central.


Gonzalez P.L.,University of Los Andes, Chile | Carvajal C.,University of Los Andes, Chile | Cuenca J.,University of Los Andes, Chile | Alcayaga-Miranda F.,University of Los Andes, Chile | And 5 more authors.
Stem Cells Translational Medicine | Year: 2015

Mesenchymal stem cells (MSCs) of placental origin have become increasingly translational owing to their abundance and accessibility. MSCs of different origin share several features but also present biological differences that might point to distinct clinical properties. Hence, mixing fetal and maternal cells from the same placenta can lead to contradicting results. We analyzed the biological characteristics of haploidentical MSCs isolated from fetal sources, including the umbilical cord (UC-MSCs) and chorion (Ch-MSCs), compared with maternal decidua MSCs (Dc-MSCs). All MSCs were analyzed for general stem cell properties. In addition, immunosuppressive capacity was assessed by the inhibition of T-cell proliferation, and angiogenic potential was evaluated in a Matrigel transplantation assay. The comparison between haploidentical MSCs displayed several distinct features, including (a) marked differences in the expression of CD56, (b) a higher proliferative capacity for Dc-MSCs and UC-MSCs than for Ch-MSCs, (c) a diversity of mesodermal differentiation potential in favor of fetal MSCs, (d) a higher capacity for Ch-MSCs to inhibit T-cell proliferation, and (e) superior angiogenic potential of Ch-MSCs evidenced by a higher capability to form tubular vessel-like structures and an enhanced release of hepatocyte growth factor and vascular endothelial growth factor under hypoxic conditions. Our results suggest that assessing the prevalence of fetomaternal contamination within placental MSCs is necessary to increase robustness and limit side effects in their clinical use. Finally, our work presents evidence positioning fetoplacental cells and notably Ch-MSCs in the forefront of the quest for cell types that are superior for applications in regenerative medicine. © AlphaMed Press.


The invention relates to highly proliferative stem cell obtained from menstrual fluid. The menstrual stern cells (MenSCs) may be cultured in vitro and exhibit mesenchymal stem cell (MSC)-like properties and some culture and expansion advantages. This population of MenSCs, compared to the broadly studied bone marrow derived stem cells (BM-MSCs) out-performs bone marrow derived mesenchymal stem cells in proliferation rate and support of hematopoietic stem cell (HSC) expansion in vitro. MenSCs demonstrate to maintain their stem cell properties over 2 years, being genetically stable, without expressing surface differentiation markers, and they also show the ability to differentiate into adipocytes, chondrocytes and osteoblast cells. MenSCs can be easily and periodically obtained, isolated and cultured.


The present invention relates to a method for providing chorion cells as a source of MSCs with cardio-myogenic and angiogenic potential, the use of these cells in clinical treatment, the obtaining of a conditioned medium of chorion-MSCs cells as inducer of angiogenesis and its use in tube-like structures generation and cardiac regeneration as an alternative to bone marrow cells in the treatment of degenerative conditions.


PubMed | Cells for Cells and University of Los Andes, Chile
Type: | Journal: Stem cell research & therapy | Year: 2015

Stem cells isolated from menstrual fluid (MenSCs) exhibit mesenchymal stem cell (MSCs)-like properties including multi-lineage differentiation capacity. Besides, menstrual fluid has important advantages over other sources for the isolation of MSCs, including ease of access and repeated sampling in a noninvasive manner. Such attributes allow the rapid culture of MenSCs in numbers that are sufficient for therapeutical doses, at lower cell passages.In this study, we advance the characterization of MenSC populations in comparison to bone marrow derived mesenchymal stem cells (BM-MSCs) with regards to proliferation, lineage differentiation, migration potential, secretion profile and angiogenic properties in vitro and in a matrigel plug assay in mice. We additionally tested their ability to support hematopoietic stem cell (HSC) expansion in vitro.The phenotypic analysis of MenSCs revealed a profile largely similar to the BM-MSCs with the exception of a higher expression of the adhesion molecule CD49a (alpha1-integrin). Furthermore, the fibroblast colony forming units (CFU-F) from MenSCs yielded a 2 to 4 fold higher frequency of progenitors and their in vitro migration capacity was superior to BM-MSCs. In addition, MenSCs evidenced a superior paracrine response to hypoxic conditions as evidenced by the secretion of vascular endothelial growth factor and basic fibroblast growth factor and also improved angiogenic effect of conditioned media on endothelial cells. Furthermore, MenSCs were able to induce angiogenesis in a matrigel plug assay in vivo. Thus, an 8-fold increase in hemoglobin content was observed in implanted plugs containing MenSCs compared to BM-MSCs. Finally, we demonstrated, for the first time, the capacity of MenSCs to support the ex-vivo expansion of HSCs, since higher expansion rates of the CD34+CD133+ population as well as higher numbers of early progenitor (CFU-GEMM) colonies were observed in comparison to the BM source.We present evidence showing superiority of MenSCs with respect to several functional aspects, in comparison with BM-MSCs. However, the impact of such properties in their use as adult-derived stem cells for regenerative3 medicine remains to be clarified.


News Article | December 1, 2016
Site: www.prnewswire.co.uk

SAN JUAN, Porto Rico, 1er décembre 2016 /PRNewswire/ -- Ces deux derniers jours, Porto Rico a été la plaque tournante du secteur des sciences de la vie lors du Biolatam® 2016, un événement qui a réuni plus de 250 leaders des secteurs biotechnologique, pharmaceutique et des technologies pour des échanges sur les dernières innovations. Organisé par EBD Group en collaboration avec ASEBIO, cet événement a permis à Porto Rico de mettre en lumière la vibrante communauté des sciences de la vie de l'île ainsi que les possibilités de partenariat et d'investissement qui s'offrent aux dirigeants des sociétés biopharmaceutiques d'Amérique latine et du monde. Cette année, 142 entreprises de 24 pays ont participé au Biolatam. En voici l'éventail : sociétés pharmaceutiques et biotechnologiques, responsables gouvernementaux, dirigeants universitaires, associations sectorielles, firmes de capital-risque, et de capital-investissement, sociétés financières institutionnelles. Ce groupe diversifié a créé l'environnement idéal pour des discussions approfondies sur la fabrication, les essais cliniques et le cycle de développement des médicaments en Amérique latine, ainsi que sur la prévention et le diagnostic des maladies tropicales, entre autres sujets. À l'ordre du jour figuraient aussi : panels de discussion avec des conférenciers prestigieux, présentations de sociétés latino-américaines innovantes, et exposition animée. À l'aide du logiciel partneringONE®, les participants ont pu programmer des réunions de 30 minutes. Ils ont tiré parti des occasions de rencontres pour créer des liens de collaboration dans les différents domaines qu'ils représentent. « Biolatam nous donne la possibilité d'ouvrir nos portes à la communauté latino-américaine. À Porto Rico, la science est un atout de développement et de croissance économique. L'île possède une riche biodiversité et sa position géographique ainsi que les incitations disponibles offrent, aux sociétés qui veulent se développer, des conditions idéales.  Quand les entreprises découvrent les possibilités d'expansion qu'offre Porto Rico, cela stimule notre croissance et dégage une voie prometteuse pour notre secteur de la recherche », a déclaré Lucy Crespo, PDG du Puerto Rico Science, Technology and Research Trust. « L'événement de cette année a réuni avec succès à Porto Rico les dirigeants biopharmaceutiques du monde entier. Tous recherchent, pour leurs activités, des opportunités de développement en Amérique latine. La capacité de rencontrer autant de leaders de l'industrie est certainement la clé d'un futur développement commercial. Nos participants ont créé de précieuses relations qui vont continuer à prolonger les réussites auxquelles nous assistons chaque année au Biolatam », a confié Anna Chrisman, directrice générale de groupe, EBD Group. Liste des principaux conférenciers de l'événement : Rolando Castro, PDG, Cognitiva IBM Watson Strategic Partner; Eugenio Torres, directeur associé, Ferraiuoli LLC; Sebastián Vidal, directeur exécutif, Parallel18; Carola Schropp, directrice générale, Hayim Group; Maroun Khoury, directeur scientifique en chef, Cells for Cells; et Morrie Ruffin, directeur associé, directeur adjoint et directeur général, Alliance for Regenerative Medicine. Compléments d'information : Suivez Biolatam sur Twitter : @EBDGroup (hashtag #Biolatam) ou sur Facebook. À propos d'EBD Group EBD Group est une société de partenariat leader dans le secteur mondial des sciences de la vie. Depuis 1993, des sociétés biotechnologiques, pharmaceutiques et du secteur des dispositifs médicaux tirent parti des conférences de partenariat, des technologies et des services d'EBD Group pour identifier des débouchés commerciaux et nouer des relations stratégiques essentielles à leur succès. Les conférences organisées par EBD Group se tiennent avec le soutien d'entreprises de tout premier plan et d'associations professionnelles internationales, parmi lesquelles : Le service Web de partenariat sophistiqué d'EBD Group, partneringONE®, sert de moteur de partenariat lors de nombreux événements tiers à travers le monde, et partnering360® est la communauté en ligne ouverte des négociateurs dans les sciences de la vie qui renforce les expériences tout au long de l'année. Branchez-vous sur Insight d'EBD Group pour avoir accès à toute l'actualité qui influence les stratégies commerciales dans le secteur des sciences de la vie. EBD Group est une société Informa. Informa est le plus grand organisateur public d'expositions, de conférences et de formations au monde. EBD Group gère des bureaux aux États-Unis et en Europe. Pour de plus amples informations, consultez le site www.ebdgroup.com.


News Article | November 30, 2016
Site: www.prnewswire.co.uk

SAN JUAN, Puerto Rico, Nov. 30, 2016 /PRNewswire/ -- Over the past two days, Puerto Rico was the hub for life sciences activity at Biolatam® 2016, in which more than 250 leaders from the biotech, pharmaceutical and technology industry came together to network and discuss the latest innovations. The event, hosted by EBD Group in collaboration with ASEBIO, enabled Puerto Rico to showcase the island's vibrant life science community along with opportunities for partnerships and investment to Latin American and global biopharma leaders. This year, Biolatam was attended by 142 companies from 24 countries. Participants ranged from pharmaceutical and biotech companies, to government officials, academic leaders, industry associations, venture capital, private equity and institutional financial firms. This diverse group created the ideal environment for key discussions regarding manufacturing in Latin America, clinical trials and the drug development cycle, and tropical diseases prevention and diagnostics, among other topics. The event included a full program of panels with prestigious speakers, presentations from innovative Latin American companies, a lively exhibition, and participants could schedule 30-minute meetings using partneringONE® software. These afforded participants the opportunity to network and create connections for collaboration in the different fields they represent. "Biolatam gives us the opportunity to open our doors to the Latin American community. Science in Puerto Rico is key for its development and economic growth. The island has rich biodiversity and its geographical position together with the available incentives is a great place for companies to expand.  When companies see Puerto Rico as a possibility for expansion, it spurs growth and continues our science sector on a promising path," said Lucy Crespo, CEO of the Puerto Rico Science, Technology and Research Trust. "This year's event was successful in bringing together biopharma leaders from around the world to Puerto Rico in search of opportunities to expand their businesses in Latin America. The ability to network with so many industry leaders is definitely the key to future business development. Our participants created valuable connections that will continue expanding the success stories we have every year with Biolatam," said Anna Chrisman, Group Managing Director, EBD Group. Notable speakers at the event included Rolando Castro, CEO, Cognitiva IBM Watson Strategic Partner; Eugenio Torres, Managing Partner, Ferraiuoli LLC; Sebastián Vidal, Executive Director, Parallel18; Carola Schropp, Managing Director, Hayim Group; Maroun Khoury, Chief Scientific Officer, Cells for Cells; and Morrie Ruffin, Managing Partner, Adjuvant Partners and Managing Director, Alliance for Regenerative Medicine. Additional information: Follow Biolatam on Twitter: @EBDGroup (hashtag #Biolatam) or on Facebook. About EBD Group EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success. EBD Group's conferences are run with the support of leading corporations and international trade associations and include: EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year. Tune into EBD Group's Insight for timely coverage of news that influences the business strategies of the life science industry. EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world. EBD Group has offices in the USA and Europe. For more information please visit www.ebdgroup.com.

Loading Cells for Cells collaborators
Loading Cells for Cells collaborators